Platelets and Hemostasis: The Role of Glycoprotein IIb/IIIa in Platelet Aggregation

Razzuk, Maruf A.; Pierce, Tada B.; Razzuk, Aziz M.

doi:10.1080/08998280.1997.11930019

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown to prevent thrombus formation after vascular injury and to be effective in reducing early reocclusion following coronary interventional procedures ( 13,19). Abciximab is a popular drug at BUMC and ranks in the top in annual pharmaceutical expenditures (The Baylor Drug Newsletter, June 1998; 10 [6]).…”

Section: Gpllblllla Inhibitorsmentioning

confidence: 99%

“…The PURSUIT trial confirmed that in patients with unstable angina or non-Qvwave myocardial infarction, eptifibatide injection reduces the combined incidence of death or myocardial infarction, regardless of patient management strategy. This product became available in June 1998 and may prove to be as effective as abciximab in maintaining coronary artery patency (13,20).…”

Section: Gpllblllla Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

A Comprehensive Review of the Physiology of Hemostasis and Antithrombotic Agents

Pierce

Razzuk

et al. 1999

Baylor University Medical Center Proceedings

Self Cite

View full text Add to dashboard Cite

Section: Gpllblllla Inhibitorsmentioning

confidence: 99%

Section: Gpllblllla Inhibitorsmentioning

confidence: 99%

A Comprehensive Review of the Physiology of Hemostasis and Antithrombotic Agents

Pierce

Razzuk

et al. 1999

Baylor University Medical Center Proceedings

Self Cite

View full text Add to dashboard Cite

New Approaches in P2Y12 Receptor Blocker Drugs Use

Fakıoğlu

Yardım-Akaydin

2022

Frontiers in Cardiovascular Drug Discovery

View full text Add to dashboard Cite

 Thienopyridine-derived clopidogrel, prasugrel, cyclopentyltriazole pyrimidine-derived ticagrelor, and non-thienopyridine-derived ATP analogue cangrelor block the P2Y12 component of ADP receptors on the platelet surface. This prevents activation of the GPIIb/IIIa receptor complex, thereby reduces platelet aggregation. The platelet activation pathway caused by ADP is blocked by P2Y12, and therefore, these drugs have a crucial role in preventing ischemic complications in patients undergoing acute coronary syndrome, including unstable angina, myocardial infarction, and percutaneous coronary intervention. In addition, the use of P2Y12 inhibitors for secondary prevention has also been focused on in clinical studies. The results of recent studies show a lot of variances in terms of duration of use, dosage, and individualized treatment management. The main concern in the clinical use of P2Y12 is dual antiplatelet therapy (with aspirin and a P2Y12 receptor blocker) following intracoronary stenting to prevent stent thrombosis. However, there are also other multifactorial variables in terms of P2Y12 inhibitor use. In this chapter, current and precise medicines regarding P2Y12 inhibitor use are evaluated, from gene testing to escalation and de-escalation strategies. Taking all these into account, providing appropriate drugs selection considering treatment time, onset time, duration of use, side effect profile, treatment limitations, and evaluating and interpreting differences in clinical use based on randomized trials will shed light on coronary heart disease treatment choice. 

show abstract

Platelets and Hemostasis: The Role of Glycoprotein IIb/IIIa in Platelet Aggregation

Cited by 2 publications

References 12 publications

A Comprehensive Review of the Physiology of Hemostasis and Antithrombotic Agents

A Comprehensive Review of the Physiology of Hemostasis and Antithrombotic Agents

New Approaches in P2Y12 Receptor Blocker Drugs Use

Contact Info

Product

Resources

About